GermanyGuido Oelkers has been appointed as the new CEO of BioNTech, set to take over from founder Ugur Sahin by February 1, 2027. Sahin and his wife, Ozlem Tureci, who co-founded the company, plan to leave BioNTech by the end of 2026 to establish a new venture focused on developing next-generation mRNA-based medications. They intend to remain shareholders in BioNTech. The search for Tureci’s successor is progressing according to plan, the company stated. BioNTech is currently focusing on critical phases of development, aiming for approvals of several cancer drugs by 2030. Recently, the company announced plans to close multiple production sites in Germany, Singapore, and locations inherited from its acquired competitor Curevac, potentially affecting up to 1,860 jobs.
Bias read (Center): The article reports on corporate leadership changes at BioNTech, including the departure of founders and their future plans. It provides factual information about management transitions, strategic goals, and operational decisions without overtly favoring any political perspective. The content does,
